Saruparib demonstrates early efficacy in breast cancers with DNA repair defects in Phase I/II trial
The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancers, according to results ...
Apr 8, 2024
0
0